Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Bamethan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 6/20 | 0.47 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.46 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.46 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | BLM | P54132 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bamethan SCHEMBL1568806 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM | |
| Bamethan SCHEMBL21693928 | 0.99 | ALDH1A1 (0.49) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM | |
| Bamethan SCHEMBL23466818 | 0.97 | ALDH1A1 (0.49) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM | |
| Bamethan SCHEMBL19329744 | 0.92 | ALDH1A1 (0.58) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM | |
| Bamethan SCHEMBL120958 | 0.92 | ALDH1A1 (0.58) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM | |
| Bamethan SCHEMBL6456972 | 0.91 | ALDH1A1 (0.56) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM | |
| SCHEMBL19329906 | 0.89 | ALDH1A1 (0.54) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM | |
| SCHEMBL19329761 | 0.89 | ALDH1A1 (0.54) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM | |
| Acetic Acid SCHEMBL20915051 | 0.86 | ADRB2 (0.50) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM | |
| Acetic Acid SCHEMBL19329934 | 0.86 | ADRB2 (0.50) | ALDH1A1HIF1ASMN1; SMN2KDM4EBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120054499-A | Slurry bed hydrogenation iron-based catalyst and preparation method and application thereof | 中国石油天然气股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2025054202-A1 | METHOD OF SCREENING A SAMPLE COMPRISING A TRANSGENE WITH A UNIQUE BARCODE | SANA BIOTECHNOLOGY, INC. (US) | 2025-03-13 | — | — | WO | claimed |
| CN-119351270-A | Composite microbial inoculum and preparation method and application thereof | 塔里木大学 | 2025-01-24 | — | — | CN | claimed |
| CN-118515575-B | Ammonium methyl cyclic acid salt and preparation method and application thereof | 上海优斐斯生物科技有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-118515575-A | Ammonium methyl cyclic acid salt and preparation method and application thereof | 上海优斐斯生物科技有限公司 | 2024-08-20 | — | — | CN | claimed |
| WO-2024163952-A2 | IDENTIFICATION OF NOVEL SAFE HARBOR SITES FOR THE STABLE EXPRESSION OF FUSOGEN LENTIVIRAL VECTOR | SANA BIOTECHNOLOGY, INC. (US) | 2024-08-08 | — | — | WO | claimed |
| CN-117935020-A | Non-invasive load identification method based on load high-frequency characteristic imaging | 杭州戈虎达科技有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-116756739-A | Gold-free chip hardware Trojan horse detection method based on DenseBlock and attention mechanism under gram angle field transformation pretreatment | 桂林电子科技大学 | 2023-09-15 | — | — | CN | claimed |
| EP-4076395-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-10-26 | — | — | EP | claimed |
| CN-110708956-B | Microcapsules comprising cycloheptanether and polyurea derived from diphenylmethane diisocyanate or an oligomer thereof in the core | 巴斯夫农业公司 | 2022-10-04 | — | — | CN | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0783029-A1 | Production method of beta-type copper phthalocyanine pigment | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1997-07-09 | — | — | EP | claimed |
| EP-0204987-B1 | MEDICINE CONTAINING VITAMIN E FOR IMPROVING THE PROPERTIES OF BLOOD | Ismail, Roshdy, Dr. (DE) | 1991-11-21 | — | — | EP | claimed |
| EP-0152106-B1 | ANTIRHEUMATIC COMPOSITIONS | Ismail, Roshdy, Dr. (DE) | 1991-09-25 | — | — | EP | claimed |
| EP-0151987-B1 | MEANS FOR THE TREATMENT OF DISEASES OF THE VEINS AND THE ANAL REGION | Ismail, Roshdy, Dr. (DE) | 1991-05-29 | — | — | EP | claimed |
| US-4782093-A | VASODILATOR | TAPOLYAI MIHALY A (US) | 1988-11-01 | — | — | US | claimed |
| US-4612194-A | VITAMIN E, VASODILATORS | ROSHDY ISMAIL | 1986-09-16 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | ADRB2 776/4885ADRB1 502/4885CHRM2 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.